ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Another course of action—which may be different from other CML experts’ opinions —would be to continue with the same TKI and monitor the patient’s BCR::ABL1 transcripts at frequent intervals (every 3 months if transcripts >0.1%; every 6 months if ≤0.1%).